GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
GeneDx (Nasdaq: WGS), a leader in genomic and clinical insights, has announced it will release its financial results for Q1 2023 on May 9, 2023, after market close. The event will include a conference call at 4:30 p.m. ET, hosted by President Katherine Stueland and CFO Kevin Feeley. Investors can register online to participate in the call, with both live and archived webcasts available on the GeneDx investor relations website.
GeneDx focuses on providing personalized health insights that inform diagnoses and treatment options, utilizing one of the largest rare disease data sets to support precision medicine. The company's efforts aim to enhance drug discovery and advance healthcare standards.
- GeneDx is positioned to leverage one of the largest rare disease data sets, enhancing its competitive edge in precision medicine.
- The upcoming financial results and conference call may provide insights into the company's growth trajectory.
- None.
STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023. On the same day, Katherine Stueland, President and Chief Executive Officer and Kevin Feeley, Chief Financial Officer will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.
Conference Call Details
Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.
About GeneDx
GeneDx, (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
Investor Relations Contact:
Tricia Truehart
investors@GeneDx.com
Media Contact:
Maurissa Messier
press@GeneDx.com
FAQ
When will GeneDx release its Q1 2023 financial results?
What time is the GeneDx conference call for Q1 2023 results?
Who will host the GeneDx Q1 2023 conference call?
How can I listen to the GeneDx conference call?
What is the main focus of GeneDx?
